Literature DB >> 16086036

Neuroprotective effect of paeoniflorin on cerebral ischemic rat by activating adenosine A1 receptor in a manner different from its classical agonists.

Da-Zhi Liu1, Ke-Qiang Xie, Xin-Quan Ji, Yang Ye, Cheng-Liang Jiang, Xing-Zu Zhu.   

Abstract

The effects of paeoniflorin (PF), a compound isolated from Paeony radix, on neurological impairment and histologically measured infarction volume following transient and permanent focal ischemia were examined in Sprague-Dawley rats. In transient ischemia model, rats were subjected to a 1.5-h occlusion of the middle cerebral artery (MCA). The administration of PF (2.5 and 5 mg kg(-1), s.c.) produced a dose-dependent decrease in both neurological impairment and the histologically measured infarction volume. Similar results were also obtained when PF (2.5, 5, and 10 mg kg(-1), s.c.) was given in permanent ischemia model. The neuroprotective effect of PF (10 mg kg(-1), s.c.) was abolished by pretreatment of DPCPX (0.25 mg kg(-1), s.c.), a selective adenosine A1 receptor (A1R) antagonist. PF (10, 40, and 160 mg kg(-1), i.v.) had no effect on mean arterial pressure (MAP) and heart rates (HR) in the conscious rat. Additionally, PF (10(-3) mol l(-1)) had no effect on noradrenaline- (NA-) or high K+ concentration-induced contractions of isolated rabbit primary artery. In competitive binding experiments, PF did not compete with the binding of [3H]DPCPX, but displaced the binding of [3H]NECA to the membrane preparation of rat cerebral cortex. This binding manner was distinguished from the classical A1R agonists. The results demonstrated that activation of A1R might be involved in PF-induced neuroprotection in cerebral ischemia in rat. However, PF had no 'well-known' cardiovascular side effects of classical A1R agonists. The results suggest that PF might have the potential therapeutic value as an anti-stroke drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086036      PMCID: PMC1751175          DOI: 10.1038/sj.bjp.0706335

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

Review 1.  Mechanisms of cerebral ischemia: intracellular cascades and therapeutic interventions.

Authors:  D L Small; A M Buchan
Journal:  J Cardiothorac Vasc Anesth       Date:  1996-01       Impact factor: 2.628

2.  Effects of an A1 adenosine receptor agonist on the neurochemical, behavioral and histological consequences of ischemia.

Authors:  A Héron; D Lekieffre; E Le Peillet; F Lasbennes; J Seylaz; M Plotkine; R G Boulu
Journal:  Brain Res       Date:  1994-04-04       Impact factor: 3.252

3.  Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model.

Authors:  L Belayev; O F Alonso; R Busto; W Zhao; M D Ginsberg
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

4.  8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo.

Authors:  E A Van Schaick; R A Math-ot; J M Gubbens-Stibbe; M W Langemeijer; H C Roelen; A P Ijzerman; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1997-11       Impact factor: 4.030

5.  Protective effect of adenosine on the anoxic damage of hippocampal slice.

Authors:  M Mori; T Nishizaki; Y Okada
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

Review 6.  Animal models of stroke: do they have value for discovering neuroprotective agents?

Authors:  A Richard Green; Tomas Odergren; Tim Ashwood
Journal:  Trends Pharmacol Sci       Date:  2003-08       Impact factor: 14.819

7.  Differential activation of adenosine receptors decreases N-type but potentiates P-type Ca2+ current in hippocampal CA3 neurons.

Authors:  D J Mogul; M E Adams; A P Fox
Journal:  Neuron       Date:  1993-02       Impact factor: 17.173

8.  Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rats.

Authors:  E-Jian Lee; Hung-Yi Chen; Tian-Shung Wu; Tsung-Ying Chen; Issam A Ayoub; Kenneth I Maynard
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

Review 9.  Neuroprotective role of adenosine in cerebral ischaemia.

Authors:  K A Rudolphi; P Schubert; F E Parkinson; B B Fredholm
Journal:  Trends Pharmacol Sci       Date:  1992-12       Impact factor: 14.819

10.  Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.

Authors:  R A Mathôt; E A van Schaick; M W Langemeijer; W Soudijn; D D Breimer; A P Ijzerman; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

View more
  42 in total

1.  Paeoniflorin ameliorates ischemic neuronal damage in vitro via adenosine A1 receptor-mediated transactivation of epidermal growth factor receptor.

Authors:  Min Zhong; Wan-ling Song; Ye-chun Xu; Yang Ye; Lin-yin Feng
Journal:  Acta Pharmacol Sin       Date:  2015-02-09       Impact factor: 6.150

2.  Protective Effects of Paeoniflorin Against MPP(+)-induced Neurotoxicity in PC12 Cells.

Authors:  Meizhu Zheng; Chunming Liu; Yajun Fan; Dongfang Shi; Yuchi Zhang
Journal:  Neurochem Res       Date:  2016-04-06       Impact factor: 3.996

3.  Paeoniflorin Atttenuates Amyloidogenesis and the Inflammatory Responses in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Hong-Ri Zhang; Jing-Hua Peng; Xiao-Bing Cheng; Bao-Zhong Shi; Mao-Ying Zhang; Ru-Xiang Xu
Journal:  Neurochem Res       Date:  2015-06-12       Impact factor: 3.996

4.  Paeoniflorin exerts analgesic and hypnotic effects via adenosine A1 receptors in a mouse neuropathic pain model.

Authors:  Dou Yin; Yuan-Yuan Liu; Tian-Xiao Wang; Zhen-Zhen Hu; Wei-Min Qu; Jiang-Fan Chen; Neng-Neng Cheng; Zhi-Li Huang
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

Review 5.  Danggui-Shaoyao-San: New Hope for Alzheimer's Disease.

Authors:  Xin Fu; QiuHong Wang; ZhiBin Wang; HaiXue Kuang; Pinghui Jiang
Journal:  Aging Dis       Date:  2015-12-20       Impact factor: 6.745

6.  A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury.

Authors:  I-Chen Yu; Ping-Chang Kuo; Jui-Hung Yen; Hallel C Paraiso; Eric T Curfman; Benecia C Hong-Goka; Robert D Sweazey; Fen-Lei Chang
Journal:  Transl Stroke Res       Date:  2017-06-17       Impact factor: 6.829

7.  Neuroprotective effect of paeoniflorin on H2O2-induced apoptosis in PC12 cells by modulation of reactive oxygen species and the inflammatory response.

Authors:  Peng Li; Zhaohui Li
Journal:  Exp Ther Med       Date:  2015-03-16       Impact factor: 2.447

8.  Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor.

Authors:  Hua-Qing Liu; Wei-Yu Zhang; Xue-Ting Luo; Yang Ye; Xing-Zu Zhu
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

9.  Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.

Authors:  Da-Zhi Liu; Xi-Yuan Cheng; Bradley P Ander; Huichun Xu; Ryan R Davis; Jeffrey P Gregg; Frank R Sharp
Journal:  Neurobiol Dis       Date:  2008-02-09       Impact factor: 5.996

10.  Protective effect of paeoniflorin against optic nerve crush.

Authors:  Jing Li; Xinchun Xiong; Yunhai Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.